More

Building Block Catalogue

225 Thousand compounds in stock

Original and unique

Make-on-demand
Building Blocks

210 Million novel building blocks

Reliable supply

Custom Synthesis

Over 650 highly skillful chemists

Unique synthesis technologies

Library Synthesis

14 Billion REAL compounds and

Custom Library Synthesis

FTE Chemistry Support

On site access to all Enamine stock BB’s

Highly flexible arrangements

2 000 new building blocks are synthesized monthly. Here is an important update to our MedChem Highlights from March 2021

Recent News

  • 05 April 2021   News

    Open positions for Postdocs and Research Scientists

    We still have several funded Postdoc positions in organic chemistry to work at Enamine Ltd. (Ukraine, Kyiv) on a ERC-project “Saturated bioisosteres of benzene.”

    Start: any time.
    Please, send the application documents (motivation letter, CV, list of publications, recommendation letters) to Pavel.MykhailiukATmail.enamine.net

  • 01 March 2021   News

    Lumobiotics GmbH is part of an European consortial Project

    We are happy to announce the start of Project ALISE supported by European Commission under Horizon 2020 MSCA-RISE. As the coordinator of the Project, Enamine is involved in the development of light-controllable antibody peptide conjugates pushing the boundaries of photopharmacology towards clinical applications.

  • 24 February 2021   Press Releases

    Enamine extend collaboration with prominent Swiss Biotech

    A new multi-year drug discovery agreement will focus on CNS drug discovery

    Kyiv, Ukraine, February 24 2021 - Enamine Ltd. a provider of drug discovery services empowered with the world’s largest collections of building blocks, fragments and screening compounds announced today that it has extended its long-standing research collaboration with Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company specialized in allosteric modulation-based drug discovery and development. Enamine is providing Addex with its integrated capability in medicinal chemistry, pharmacology and ADME/PK (Absorption, Distribution, Metabolism, Excretion/Pharmacokinetics) to efficiently support Addex’ small molecule CNS drug discovery programs.

    Read press release

Upcoming events

β-Catenin/Bcl9 Protein-Protein Interaction Inhibitors library

#

1 779 compounds

In order to assemble a focused small-molecule subset to tackle this interaction, we turned our attention to the published structural data. We built our pharmacophore model taking into consideration the reported helix-helix interaction between the two biological molecules. Specifically, we investigated the key H-bonds between H358, R359 (Bcl9) and D162, D164 (β-catenin) (Figure 1). Following docking and prioritization studies of our medchem compound selection, we picked molecules that i) secured hydrogen bonding with D162/D164 and ii) exhibited a significant β-stacking/hydrophobic interaction area with β-catenin to result in 1 779-compound library.

Fig. 1.(a)β-catenin/BCL9 helix-helix interaction interface featuring key hydrogen bonds; (b) binding of β-catenin and a representative ligand from the focused subset.

[submenu-wnt-lib][/submenu-wnt-lib]

FOLLOW US

Contact us

I have read and agree with Privacy Policy of Enamine

Send me details